Point of Care Solution
Veralize’s patented technology uses state-of-the-art Graphene Carbon-Nanotubes that are mixed with two preserved regions of synthetic (single-stranded-DNA) target genome.
The nanotubes are an excellent support matrix to present the single-stranded-DNA (ss-DNA) probe fragments for hybridization with the test sample’s ss-RNA.
Test sample’s virus shell (if present) from fresh saliva samples will be broken down by our patent-pending process, thus releasing the ss-RNA within the shell.
Positive test occurs when the test sample’s ss-RNA hybridizes with the probe’s ss-DNA strands, producing an increased electric charge.
GCN support matrix
Manufactured in the US to the highest standards, our Veralize test device sensitivity is comparable to the gold standard, RT-PCR, and has clinically shown 98% accuracy. Veralize provides test results in under 7 minutes.
The Veralize system is designed to identify a wide range of cancers and infectious diseases by encoding our proprietary nanotube sensors with appropriate genetic detection information.
As infectious diseases evolve from occasional outbreaks to persistent threats, healthcare professionals and individuals will continue to seek assurance that their flu-like symptoms are not indicative of a serious infectious disease. Patients and their healthcare providers will seek precise diagnoses to ensure proper treatment.
Our saliva test offers consumers a POC alternative to lab tests (accurate, but slow and expensive) and antigen tests (cheap and fast, but 40% accurate).
Veralize offers doctors & patients a quick, accurate POC test, similar to common quick strep tests. LOI from health system for ambulatory sites.
Rapid, accurate, POC tests are needed for inpatient surgeries (LOI) and outpatient surgeries.